Quanterix closes $127M Akoya deal after competing bid
Quanterix has completed its acquisition of Akoya Biosciences, following interest from a third-party bidder who threatened to torpedo the deal that has a total enterprise value of $127 million. The...
View ArticleProKidney's stock shoots higher after mixed Phase 2 data
Kidney disease drug developer ProKidney vaulted above $1 per share this morning, despite mixed open-label Phase 2 data. The company is studying whether its lead program, a cell therapy called...
View ArticleThe highest-paid pharma and biotech CEOs of 2024
The typical CEO of a public biopharma company made $4.73 million in 2024, a 40% jump from last year’s median figure. But a handful of CEOs hauled in much larger paydays. Endpoints News compiled data ...
View ArticleRecursion takes full rights to rare genetic disorder drug; CStone...
Plus, news about Basilea, BARDA, Inventiva and CTTQ: Recursion buys full rights to oral drug: The AI-driven biotech, which recently restructured, acquired the full rights to REV102, an ...
View ArticleIn first half of 2025, novel drug approvals are in line with previous years
Thousands of FDA staff departures since April have sparked concerns within the pharma industry that novel drug approval deadlines might slip. But in the first six months of 2025, the approval numbers...
View ArticleOtsuka’s Taiho reports Phase 3 fail for Duchenne muscular dystrophy drug
An Otsuka subsidiary said Tuesday that its experimental therapy for Duchenne muscular dystrophy has failed its Phase 3 primary endpoint in a group of ambulatory patients in Japan. Taiho Pharmaceutical
View ArticleTrump hints at tariff grace period for pharma companies to onshore manufacturing
President Donald Trump said pharmaceutical companies will have a grace period of at least a year to move their manufacturing to the US before facing tariffs on their drugs. The new detail disclosed...
View Article'CRISPR Cures' center launches to make custom gene editing therapies
Scientists seeking to make personalized gene editing therapies a reality for more people have launched a new initiative to develop cures for the rarest of diseases left behind by drug companies. ...
View ArticleSupreme Court halts California order that blocked RFK Jr. from reorganizing HHS
HHS Secretary Robert F. Kennedy Jr. can go ahead with some of his plans to downsize the federal health agencies after the US Supreme Court suspended a district court order on Tuesday. The high court ...
View Article